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Abstract
Introduction The objective of this study was to analyze health
care and non-health care resource utilization under routine
medical practice in a primary care setting claims database and
to estimate the incremental average cost per patient per year of
fibromyalgia syndrome (FMS) compared with a reference
population.
Methods A 12-month cross-sectional and retrospective study
was completed using computerized medical records from a
health provider database. Analyses were conducted from the
perspective of the provider and from the viewpoint of society.
Health care and non-health care resource utilization included
drugs, complementary tests, all types of medical visits, referrals,
hospitalizations, sick leave, and early retirement because of
disability due to FMS. Patients with a diagnosis of FMS in
accordance with ICD-10 (International Statistical Classification
of Diseases and Related Health Problems, 10th revision) criteria
were included in the analysis if they had at least one claim for
FMS during the 12 months prior to the end of May 2007. A non-
FMS comparison group was also created with the remaining
subjects.
Results Of the 63,526 patients recruited for the study, 1,081
(1.7%) (96.7% of whom were women, 54.2 [10.1] years old)
met the criteria for FMS. After an adjustment for age and gender,
FMS subjects used significantly more health care resources
than the reference population and had more sick leave and the
percentage of subjects with premature retirement was also
significantly higher (P < 0.001 in all cases). As a result, FMS
subjects showed an incremental adjusted per-patient per-year
total cost of €5,010 (95% confidence interval [CI] 3,494 to
6,076, +153%, P < 0.001) on average compared with non-FMS
subjects. Significantly higher differences were observed in both
health care and non-health care adjusted costs: €614 (404 to
823, +66%) and €4,394 (3,373 to 5,420, +189%),
respectively (P < 0.001 in both cases). Annual drug expenditure
per patient on average was considerably higher in FMS patients,
€230 (124 to 335, +64%, P  < 0.001), than the reference
group.
Conclusions Under routine medical practice, patients with FMS
were associated with considerably higher annual total costs in
the primary care setting compared with the reference
population.
Introduction
Fibromyalgia syndrome (FMS) is characterized by widespread
pain, tenderness, and fatigue and is typically difficult to diag-
nose [1]. In 1990, the American College of Rheumatology
(ACR) published diagnostic criteria for FMS – namely, wide-
spread pain (both sides of the body, above and below the
waist, and in the cervical spine, anterior chest, thoracic spine,
or lower back) and pain upon digital palpation in at least 11 of
ACR: American College of Rheumatology; ANCOVA: analysis of covariance; BPI: Brief Pain Inventory; BSA: Badalona Serveis Assistencials S.A.; 
EQ-5D: five-item questionnaire on European quality of life; FIQ: Fibromyalgia Impact Questionnaire; FM: fibromyalgia; FMS: fibromyalgia syndrome; 
GERD: gasroesophageal reflux disease; ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th revision; PC: 
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18 specified tender point sites [2] – although it was not offi-
cially recognized as an illness by the World Health Organiza-
tion until 1992 [3]. FMS is a widespread disorder of unknown
etiology which affects an estimated 1% to 4% of the general
population [4]. It may occur in 2.1% to 5.7% of the general
adult population, comprising 10% to 20% of rheumatologic
consultations and 5% to 8% of primary care (PC) consulta-
tions and being the most frequent cause of general and
chronic skeletal muscular pain [5-7]. Women are about nine
times more likely than men to develop FMS [1].
The symptoms of FMS can be prolonged and debilitating. It
negatively affects the lives of patients, the people around
them, and the environment in which they live. It is one of the
rheumatic illnesses with the greatest impact on patient quality
of life, having negative consequences on physical capability,
intellectual activity, emotional condition, personal relation-
ships, professional career, and mental health to the extent that
the patient requires multiple intervention strategies [8-10]. In
recent years, fibromyalgia (FM) has acquired greater signifi-
cance and has become a first-order public health problem.
There are several reasons to justify this situation: (a) its high
level of prevalence in the general adult population, (b) insuffi-
cient knowledge of its cause and the mechanisms that pro-
duce it (decrease of the nociceptive perception threshold), (c)
absence of a curative treatment, and (d) dissatisfaction of
patients and professionals with current therapeutic
approaches [7-9]. Given the chronicity of the symptomatology
and the disability that it often produces, it is associated with
elevated levels of health care and non-health care resources,
often stemming from work absenteeism [9].
Available evidence on the cost of FMS to society has been
scant up to now, and information on the direct and indirect
costs and utilization of health care resources comes primarily
from the US, Canada, and The Netherlands [11-15]. In these
countries, the direct health care costs are considerable, and
the indirect costs, arising from employment absenteeism and
disability pensions, are double those of the general working
population. Total annual expenses for a patient with FMS entail
more than twice the expenses incurred for a patient with anky-
losing spondylitis and are similar to those of a patient with
chronic lumbalgia [11-16].
There are substantial limitations to the existing research. Sev-
eral studies were conducted well over a decade ago, and
many of the more recent ones have other shortcomings,
including small sample size and/or choice of reference group.
Moreover, many of these studies are based on questionnaire
data, which may not necessarily reflect actual patterns of utili-
zation because of problems with patient recall and/or compre-
hensiveness of questionnaire content. A large study has been
conducted in the US using a large health insurance claims
database and for the year 2005 showed an annual health care
cost per patient with FMS of $9,573, which is three times
higher than that of the reference group [14]. However, pat-
terns of medical care in the US may differ widely from those in
the European context. We have not been able to identify any
cost studies for FMS in the Spanish health system. The objec-
tive of this study was to analyze the use of health care and non-
health care resources in a primary health care setting and the
costs arising from the treatment of patients with FM under
usual medical practice conditions recorded in a Spanish
claims database. Information on the economic impact of FMS
will be useful to clinicians, payers, and researchers.
Materials and methods
Study design and data collection
A cross-sectional and multicenter study was conducted from
a retrospective review of medical outpatient records. The
study population consisted of men and women from five reno-
vated PC centers (Apenins-Montigalà, Morera-Pomar, Mont-
gat-Tiana, Nova Lloreda, and La Riera) that are managed by a
health management organization (Badalona Serveis Assisten-
cials S.A. [BSA], Barcelona, Spain) and that cover a popula-
tion of 110,440 inhabitants, 16.5% of whom are over 64 years
of age. The assigned population is primarily urban. The organ-
ization is public with a private services supply and is managed
according to a business model. The corporation staff, training
policy, organization model, and services portfolio are similar to
those of most PC centers in Catalonia (Spain), with a decen-
tralized management model and with integrated structural
services. This study is based on data obtained from an admin-
istrative medical database; consequently, it was not necessary
to be approved by an ethics committee.
We analyzed men and women (older than 18 years of age)
who were included in the database (n = 63,526). FMS
patients, with a code in accordance with ICD-10v10 (Interna-
tional Statistical Classification of Diseases and Related Health
Problems, 10th revision) (code M79.7) criteria for this disor-
der, were included in the analysis if they had at least one claim
for FMS between 1 May 2006 and 30 April 2007. Subjects
who did not have a claim for FMS were included in a reference
group. Subjects referred to other PC centers, belonging to
other geographic areas, visiting integrated specialists, or hav-
ing serious psychiatric illnesses were excluded from the study.
The clinical diagnosis of FMS was based on the presence of
chronic and generalized bone and muscular pain, according to
the ACR classification criteria established in 1990 [2]. FMS is
defined by a history of at least 3 months of generalized and
continuous pain on both sides of the body, above and below
the waist, and axial skeleton, cervical, or front chest pain. Fur-
thermore, there should be pain to touch in at least 11 out of
the following 18 symmetric points: occipital, low cervical, tra-
pezium, supraspinal, second intercostal space in the chondro-
costal joint, epicondyle, gluteal, greater trochanter, and knee.
The study was performed in two phases. In the first, informa-
tion on the primary sociodemographic and clinical (comorbid-Available online http://arthritis-research.com/content/11/2/R54
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ity) variables and the use of health care and non-health care
resources (days of leave from work, subjects with permanent
disability) related to the FMS was obtained from the database,
omitting any data that could identify the patient. Information on
resources used by patients as a consequence of their illness
which were not financed by the National Health System such
as special diets or non-pharmacological treatments (such as
massages or acupuncture) was not gathered as it was not
included in the database. In the second phase, telephone
interviews were conducted of a sample of FMS patients
selected at random from the database to evaluate self-per-
ceived health and well-being. Interviews were conducted by
members of the research team. The surveys averaged 40 min-
utes in duration and were conducted in the months of May and
June of 2007, immediately after the data on the use of health
care and non-health care resources were collected from the
database. Prior to the interview, the selected patients were
contacted to inform them about the study, obtain their consent
for participation, and provide a verbal guarantee of confidenti-
ality. Interviewers were previously subjected to training on the
instruments of self-perceived health which had to be adminis-
tered (see 'Patient-reported outcome instruments used in the
study'). Selection of individuals was made using probability
techniques (simple random sample stratified by age and gen-
der), and sample size was calculated by adopting the following
parameters: confidence level of 95%, bilateral test, infinite
populations, precision of 2%, and anticipated prevalence of
the illness of 2.2%. The total number of subjects to be inter-
viewed was 212. Persons with a physical or psychiatric disa-
bility that limited them from responding to a telephone
questionnaire, persons with incorrect phone numbers, sub-
jects who were not located after three calls made on different
days, and those who declined to participate were considered
losses to the study.
The primary recorded data were age (continuous and by
ranges), gender, and personal history (comorbidities) obtained
from the PC International Classification (CIAP-2) [17], 7th
component of diseases and health problems, consisting of
blood hypertension (K86, K87), dyslipidemia (T93), diabetes
mellitus (T90, all types), active smoking (P17), alcoholism
(P15), obesity (T82), ischemic cardiopathy (K74, cardiac
ischemia with angina; K75, acute myocardial infarction; K76,
coronary ischemia), cerebrovascular events (including stroke
and transient ischemic attack), presence of a cardiovascular
event, chronic obstructive pulmonary disease (R95, chronic
obstruction of airflow), bronchial asthma (R96), depressive
syndrome (P70), failure of all types (heart, liver, and renal),
neuropathy, malignancy, and dementia. Morbidity burden
(patient's severity) and the number of health problems
attended per patient per year were assessed using the Charl-
son index [18] and the resource utilization band (RUB) method
[19].
Health and non-health care resources and cost 
estimation
Health resource utilization obtained from center records con-
sisted of visits or appointments conducted at the PC center,
referrals to reference specialists, requests for complementary
support tests, emergency room visits, hospitalizations, and
drug prescriptions financed by the National Health Service.
Non-health care resource utilization consisted of workdays
lost in the active population and early retirement (<65 years
old) because of permanent disability due to FMS. The cost
system design was defined by taking into account the charac-
teristics of the organization and the level of development of
available information systems. The unit of assistance used as
the base for final calculation was the cost per patient assisted
during the study period. Fixed costs (with imputation criteria)
and variable costs were considered in accordance with their
dependence on the volume of activity. Costs related to staff
(salaries), consumer goods, and a set of expenses related to
external services, in accordance with the General Accountabil-
ity Plan for Health Care Centers, were considered fixed costs
(structural), and those associated with diagnostic, therapeutic,
or referral requests performed by staff at the center were con-
sidered variable costs. Economic assessments were gener-
ated for (a) complementary tests, including laboratory tests
(mean expenses per application), conventional radiology (fee
per each test requested), and support tests (fee per each test
requested); (b) ordinary or urgent referrals to reference spe-
cialist doctors or to hospitals (referral adapted fee); (c) pre-
scriptions (acute, chronic, or requested medical prescriptions;
market price per container), and (d) workdays lost (profes-
sional average salary) and information regarding early retire-
ment (before 65 years) because of permanent disability due to
FMS. The fees used were obtained from analytical accounta-
bility studies conducted by the organization or from CatSalut
established prices [20]. The mean cost per visit was obtained
from average fixed costs, and a final direct distribution was
made for each patient assisted during the study period.
Indirect costs were calculated according to human capital
methodology [21,22]. Two main components of these costs
were calculated. First, workdays lost due to sick leave in the
active population, as a result of FMS, were calculated as the
sum of the yearly number of workdays lost (recorded in the
BSA database during the study period) multiplied by daily
average salary in active subjects. Second, we added the cost
to society for those patients with early retirement prior to 65
years of age (permanent disability from usual working activity)
due to FMS. These costs were calculated as the sum of the
average salary for the calendar year (which is considered to be
an opportunity cost) plus the pension received from Social
Security because of the permanent disability from performing
usual tasks, resulting in early retirement prior to 65 years of
age. The annual average professional salary in the year 2006
was €18,714 and the pension received because of a perma-
nent disability from Social Security was €1,906 per year perArthritis Research & Therapy    Vol 11 No 2    Sicras-Mainar et al.
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subject. Thus, the total cost per patient (Cp) was Cp = (mean
cost per visit × number of visits [average fixed costs]) + varia-
ble costs + indirect costs. All costs were expressed in euros
for the year 2007 and are shown as mean cost per patient per
year.
Patient-reported outcome instruments used in the study
Self-perceived health included self-assessment of pain inten-
sity and impact on various facets of the patient's life, health
condition, and quality of life as it relates to health. Validated
Spanish versions of the following health instruments were
administered: (a) Fibromyalgia Impact Questionnaire (FIQ)
[23,24], (b) the modified Brief Pain Inventory (BPI)-Short Form
[25,26], and (c) the five-item questionnaire on European qual-
ity of life (EQ-5D) [27,28]. The FIQ was developed in an
attempt to capture the total spectrum of problems related to
FM and responses to therapy. The FIQ is a self-administered
instrument that takes approximately 3 to 5 minutes to com-
plete. It is scored in such a way that a higher score indicates a
greater impact of the syndrome on the person. Each of the 10
items has a maximum possible score of 10. Thus, the maximum
possible score is 100. The first item consists of 11 questions
that make up a physical function scale. The 11 questions are
scored and added to yield one physical impairment score.
Each item is rated on a 4-point Likert-type scale. Items 2 and
3 have a 0 to 7 score range and then require standardization
to a 0 to 10 scale. Items 4 through 10 are scored in a 0 to 10
score range and they do not require standardization. Finally,
the FIQ total store is calculated by adding the scores of all 10
items [24]. The BPI is an instrument developed for use in epi-
demiological studies and clinical trials to evaluate the effec-
tiveness of pain treatment. It consists of two dimensions: pain
intensity (four items) and interference with activities (seven
items). Each one of the items is scored using a numeric rating
scale from 0 (absence of pain/interference with daily life) to 10
(worst pain imaginable/maximum impact on daily life). Scores
for each subscale are obtained using the sums of the partial
scores from the corresponding items divided by the number of
items in each subscale, although a direct interpretation of each
one of the items individually can be made [26]. The pain sever-
ity subscale can be interpreted in a categorized manner in
three levels of intensity: mild (<4), moderate (≥ 4 to <7), and
severe (≥ 7) [29]. A score greater than or equal to 5 on the
interference subscale is considered to indicate the existence
of pain interference in the patient's daily activities (this inter-
pretation is also valid for each one of the items on the sub-
scale) [30]. The EQ-5D was designed to assess the patient's
perceived health status. This is a five-item generic measure of
health status to assess the level of abnormality on five dimen-
sions: movement, self-care, daily life activities, pain/discom-
fort, and anxiety/depression. Scores of these five items may be
used to calculate a utility index, ranging from -0.6 to 1.0, with
higher scores representing better health status. The instru-
ment also includes a 20-cm visual analogue scale (EQ-5D
VAS) ranging from 0 (the worst imaginable health status) to
100 (the best imaginable health status) [27,28].
Statistical analysis
As a step prior to analysis, in particular to the source of infor-
mation pertaining to computerized clinical records (Oficina
Médica Informatizada de Atención Primaria Windows version,
STACKS, Barcelona, Spain), data were carefully reviewed to
study the distribution of frequencies and to check possible
recording or codifying errors. The quality of computer-
obtained data was considered adequate, and legal confidenti-
ality requirements for recording were maintained as previously
mentioned. A descriptive univariate statistical analysis was
conducted, and the Kolmogorov-Smirnov test was used to
check normality of the distribution. For the bivariate analysis,
Student t tests and chi-square tests were used. A bivariate
logistic regression analysis and analysis of covariance
(ANCOVA) were conducted to adjust FMS findings (comor-
bidities, premature retirements, type of treatment, and so on)
by age and gender. Costs between reference group and FMS
patients were compared, in accordance with the recommen-
dations of Thompson and Barber [31], using an ANCOVA with
gender and age as covariates (with Bonferroni corrections for
multiple-pair comparisons).
Analyses of correlation, with Pearson product-moment coeffi-
cient calculation, were carried out to explore the possible rela-
tionship between patient-reported outcome questionnaire
responses and cost of disease (total, health care, and indirect
costs). Linear regression analyses were carried out between
costs and the interference of pain with daily activities (BPI-I
subscale with patients grouped according to the degree of
interference in 10 categories from 0–1 to 9–10) and disease
impact (FIQ total scoring expressed in decile intervals) in
which the coefficient of correlations was at least 0.2 to explore
the ability of such instruments to relate disease impact/inter-
ference with costs. The SPSS/WIN program (version 14)
(SPSS Inc., Chicago, IL, USA) was used, and a P value of less
than 0.05 was considered statistically significant.
Results
Demographics and clinical characteristics
From the 110,440 subjects assigned to the five centers ini-
tially selected, 80,775 attended PC settings during the study
period, with an intensity of use of 73.1% and a frequency of
4.7 visits per 100 inhabitants per year. Ultimately, 63,526
were recruited for the study. During the study period, 304,075
health problems and 494,122 PC visits were recorded; on
average, 0.61 health problems were attended per visit per
year. One point seven percent (n = 1,081; 95% confidence
interval 0.6% to 2.2%) of patients had a diagnosis of FMS
according to ICD-10 criteria. General characteristics, socio-
demographics, and principal comorbidities of patients studied
are presented in Table 1. The mean age of FMS subjects was
slightly but significantly higher compared with the referenceAvailable online http://arthritis-research.com/content/11/2/R54
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Table 1
Demographic and clinical characteristics of study subjects
Demographics FMS patients
n = 1,081
Reference group
n = 62,445
Statisticsa P value
Age in years, mean (SD) 54.2 (10.1) 49.1 (17.9) 16.29 <0.001
18–44 15.6 45.1 3.09 <0.001
45–64 71.2 32.9
65–84 13.0 19.8
≥ 85 0.1 2.2
Gender, percentage of females 96.7 53.5 796.02 <0.001
Pensioners, percentage 42.8 31.2 1.46 (1.26–1.70) <0.001
BMI in kg/m2, mean (SD) 28.6 (5.3) 27.4 (5.1) 7.06 <0,001
Smoking, percentage 18.2 21.0 1.35 (1.15–1.58) <0.001
Alcoholism, percentage 0.7 1.7 1.55 (0.76–3.16) 0.229
Main comorbiditiesb
Blood hypertension 27.8 21.8 1.37 (1.19–1.59) <0.001
Dyslipemia 37.0 23.3 1.94 (1.71–2.21) <0.001
Diabetes mellitus 8.4 9.1 1.09 (0.87–1.36) 0.449
Obesity/weight gain (BMI > 27 kg/m2) 41.1 31.7 1.34 (1.18–1.53) <0.001
Coronary heart disease 1.8 3.6 1.02 (0.64–1.63) 0.924
Stroke 3.3 4.1 1.38 (0.98–1.95) 0.064
Peripheral vascular disease 4.8 6.9 1.25 (0.94–1.67) 0.131
COPD 0.9 2.8 1.06 (0.56–7.17) 0.855
Asthma 6.1 4.0 1.36 (1.06–1.76) 0.018
Any neurological disorders 0.4 0.5 0.77 (0.28–2.07) 0.601
Dementia 0.4 0.9 0.88 (0.32–2.38) 0.794
Migraine 12.6 3.6 2.41 (1.99–2.92) <0.001
Major depressive disorders 40.2 10.7 3.85 (3.39–4.37) <0.001
Anxiety disorders 31.3 19.7 1.24 (1.09–1.42) 0.001
Any disease of the digestive system 70.3 54.0 1.44 (1.24–1.67) <0.001
Irritable bowel syndrome 5.1 1.2 2.56 (1.91–3.44) <0.001
GERD 14.2 5.0 2.14 (1.77–2.59) <0.001
Gastritis 22.4 11.6 1.51 (1.29–1.78) <0.001
Pain 20.5 5.5 2.94 (2.51–3.43) <0.001
Neoplasm 4.3 3.5 1.23 (0.91–1.66) 0.187
Morbidity burden
Charlson index, mean (SD) 0.29 (0.62) 0.26 (0.58) 1.71 0.089
RUB index
Low 9.8 27.2 354.8 <0.001
Moderate 76.2 52.3
High 9.7 5.7
Very high 0.8 0.5
Healthy 3.4 14.3
aValues of t or chi-square for age, body mass index (BMI), gender, age group, and morbidity burden comparisons; other values are odds ratio 
adjusted for age and gender with 95% confidence intervals in parentheses. bUnless otherwise indicated, all values are percentages. COPD, 
chronic obstructive pulmonary disease; FMS, fibromyalgia syndrome; GERD, gastroesophageal reflux disease; RUB, resource utilization band; 
SD, standard deviation.Arthritis Research & Therapy    Vol 11 No 2    Sicras-Mainar et al.
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group (54.2 [10.1] versus 49.1 [17.9], P < 0.001), whereas
the percentage of women was, as expected, significantly
higher (96.7% versus 53.5%, P  < 0.001). FMS patients
showed significant and higher prevalence of a variety of com-
mon comorbidities such as psychiatric disorders (major
depression, anxiety, and so on), neurological diseases
(migraine), pain, and digestive tract diseases (gasroesopha-
geal reflux disease [GERD], gastritis, and so on), with signifi-
cantly higher values of morbidity burden (RUB and Charlson
index). Of particular interest were migraines, major depressive
disorders, irritable bowel syndrome, GERD, and pain that had
gender- and age-adjusted odds ratios above 2 compared with
the reference population. FMS patients also showed signifi-
cantly higher values of total cholesterol, low-density lipopro-
tein cholesterol, and triglycerides compared with subjects in
the control group (Table 2).
Resource utilization and costs
As a consequence of the higher morbidity burden and preva-
lence of comorbidities, the FMS group was associated with
higher use of pain-related medications such as antidepres-
sants, long-acting opioids, analgesics, and muscle relaxants
(Table 3). Fifty-two point four percent of patients with FMS
used benzodizepines versus 19.6% in the reference group (P
< 0.001), 74.7% of subjects used nonsteroidal anti-inflamma-
tory drugs versus 39.3% (P < 0.001), 25.3% used muscle
relaxants versus 6.5% (P < 0.001), 30.5% used long-acting
opioids versus 3.8% (P < 0.001), and 63.5% used other types
of analgesics versus 33.3% (P < 0.001) in the general popu-
lation. On average, after adjustments for age and gender, sub-
jects with FMS were treated, in one year, with 1.96 more drugs
than the reference population (Table 3). In addition, patients
with FMS used significantly more health care resources (med-
ical visits, referrals to specialists, and supplementary tests),
except for hospital stays, than the reference group (Table 4). It
is particularly interesting to note that patients with FMS made,
on average, six more yearly medical visits than the reference
population: five to the PC physician and one other visit to a
specialist or to emergency services (P < 0.001 in all cases)
(Table 4). Greater use of health care resources was accompa-
nied by a higher average of workdays missed (20.9 versus 8.0
days,  P  < 0.001) and a greater number of subjects who
receive a pension from Social Security due to permanent dis-
ability before the theoretical retirement age (29.9% versus
9.5%, P < 0.001) (Table 4).
Age was positively and significantly correlated to health care
costs (r = 0.280, P < 0.001), whereas a weaker correlation,
though significant, was shown with indirect costs (r = 0.072,
P = 0.018) and total costs (r = 0.112, P < 0.001). This is
explained by the fact that costs of lost earnings are not calcu-
lated after the theoretical retirement age, only health care
costs.
The greater use of health care resources and absenteeism/
employment disability in FMS patients is accompanied by sig-
nificantly higher costs, in both the direct (except for hospitali-
zation costs) and the indirect (sick leave and early retirement)
costs. Once adjustments for age and gender were made, FMS
subjects incurred €614 more in average annual health care
costs (P < 0.001) (Table 4) and €4,397 more in the compo-
nent of indirect costs (P < 0.001) in comparison with the ref-
erence group, totaling an extra annual average cost per patient
of €5,010 (P < 0.001) (Table 4).
Self-perceived health and costs
A second analysis assessed the relationship of total costs,
direct and indirect, to the impact of FMS on self-perceived
health, as determined using the FIQ, BPI, and EQ-5D scales
mentioned above. The measures were administered to a sub-
sample of 200 patients selected at random from among the
1,081 subjects with FMS included in the database. This
Table 2
Analytical parameters by study group
Characteristic FMS patientsa
n = 1,081
Reference groupa
n = 62,445
Adjusted differences and P valueb
Systolic blood pressure, mm Hg 124.6 (17.4) 126.5 (17.5) 1.6 (-1.1–4.3); P = 0.251
Diastolic blood pressure, mm Hg 76.1 (9.9) 75.4 (10.0) 0.8 (-0.9–2.5); P = 0.337
Glucose, mg/dL 95.8 (23.3) 96.9 (27.1) 3.5 (-0.9–7.7); P = 0.116
Hemoglobin A1c, percentage 6.0 (1.5) 6.4 (1.5) 0.4 (-0.8–0.1); P = 0.115
Triglycerides, mg/dL 126.5 (120.6) 119.2 (84.1) 28.5 (12.8–44.1); P < 0.001
Total cholesterol, mg/dL 213.9 (38.4) 200.9 (40.9) 14.4 (7.7–21.1); P < 0.001
HDL-C, mg/dL 61.1 (17.3) 56.9 (17.5) 0.2 (-3.0–3.3); P = 0.913
LDL-C, mg/dL 130.3 (35.7) 123.0 (35.9) 14.1 (7.3–21.0); P < 0.001
aValues are presented as mean (standard deviation). bDifferences adjusted for age and gender. FMS, fibromyalgia syndrome; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.Available online http://arthritis-research.com/content/11/2/R54
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patient population did not differ from the overall patient sample
with FMS in the proportion of women (97.5% versus 96.5%,
respectively; chi-square = 0.26, P  = 0.612), pensioners
(38.0% versus 43.9%, respectively; chi-square = 2.06, P =
0.152), or comorbidities according to the Charlson index (chi-
square = 2.16, P = 0.142). Slightly significant differences in
the mean age were noted (53.0 [8.5] versus 54.5 [10.4] years
old, respectively; t = 1.92, P = 0.06), and as such, the sample
to whom the measures were administered was considered to
be comparable to and representative of the population of FMS
patients in the BSA database. Persons with a physical or psy-
chiatric disability that limited them from responding to a tele-
phone questionnaire (n = 2), those with incorrect phone
numbers (n = 3), subjects who were not located after three
calls made on different days (n = 5), and those who declined
to participate were considered losses to this analysis. In the
end, information from the health questionnaires was obtained
from a total of 200 patients. The mean score (standard devia-
tion) in the FIQ for this subsample was 71.7 (16.9) points, with
6.9 (1.7) and 6.8 (2.1), respectively, as mean scores on the
subscales of pain severity and interference on the BPI ques-
tionnaire. More than three quarters of the patients had pain
interference with their daily activities (score of at least 5 on the
pain interference subscale of the BPI), and 57% stated that
the condition of their health had worsened with respect to the
previous year (EQ-5D).
Total costs correlated significantly and moderately with the
degree of impact of the illness on the patient according to the
FIQ (r = 0.282, P < 0.001) due to the fact that both indirect
and health costs also were significantly correlated, though
moderately, with the FIQ (r = 0.265 and 0.202, respectively; P
< 0.001 and P  = 0.004, respectively). However, when
patients were analyzed with the responses to the FIQ grouped
by deciles, a significant linear relationship (P < 0.001) of mod-
erate intensity of the association was observed, both with total
costs (R2 = 0.55) and with indirect and health care costs (R2
= 0.51 and 0.67, respectively) (Figure 1).
Table 3
Distribution of study subjects according to principal related medications
Pain-related medication FM patients
n = 1,081
Reference group
n = 62,445
Odds ratio
(95% CI)
P value
Antiepileptics 16.0 4.3 1.18 (0.97–1.44) 0.102
Benzodiazepines 52.4 19.6 1.47 (1.27–1.70) <0.001
Sedatives and hypnotics 12.8 5.3 0.99 (0.81–1.22) 0.949
Corticosteroids 6.4 3.2 0.97 (0.73–1.29) 0.851
COX-2 inhibitors 0.6 0.2 0.81 (0.30–2.17) 0.673
NSAIDs 74.7 39.3 1.86 (1.59–2.17) <0.001
Muscle relaxants 25.3 6.5 2.20 (1.88–2.59) <0.001
Antidepressants
TCAs 22.2 1.8 5.46 (4.56–6.53) <0.001
MAOIs 0.0 0.0 0.00 (0.00–0.00) 0.999
SSRIs 36.3 9.8 2.08 (1.79–2.41) <0.001
Other antidepressants 16.3 2.2 2.90 (2.37–3.55) <0.001
Opioids
Short-acting opioids 0.1 0.1 0.20 (0.03–1.51) 0.118
Long-acting opioids 30.5 3.8 3.56 (3.02–4.21) <0.001
Antimigraine drugs
Triptans 3.5 0.9 1.05 (0.71–1.57) 0.802
Other antimigraine drugs 2.5 0.5 1.58 (1.00–2.49) 0.048
Other analgesics 63.5 33.3 1.54 (1.33–1.78) <0.001
Miscellaneous 11.6 4.4 0.94 (0.75–1.16) 0.549
Medications per year, mean (SD) 3.7 (2.0) 1.4 (1.5) 1.96 (1.73–2.18)a <0.001
Unless otherwise indicated, all values are percentages. aValue is the mean difference (95% CI) between groups adjusted by age and gender. CI, 
confidence interval; COX-2, cyclooxygenase-2; FM, fibromyalgia; MAOI, monoamine oxidase inhibitor; NSAID, nonsteroidal anti-inflammatory 
drug; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.Arthritis Research & Therapy    Vol 11 No 2    Sicras-Mainar et al.
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The intensity of the pain present in the patient, according to
the BPI pain severity subscale, also correlated in a significant
and moderate way to the total costs (r = 0.270, P < 0.001)
and indirect costs and less with the direct health care costs (r
= 0.180, P = 0.011), showing statistically significant differ-
ences (P < 0.05) when patients were grouped according to
pain intensity (Figure 2). Direct health care costs and pain
intensity due to FM were driven largely by pharmacological
costs (Figure 3). However, pain interference in general activi-
ties and daily lives of the patients measured with the BPI inter-
ference subscale correlated in a significant way with total (r =
0.340, P < 0.001), indirect (r = 0.323, P < 0.001), and health
care (r = 0.217, P = 0.002) costs. Figure 4 more clearly dem-
onstrates the very significant linear relationship (P < 0.001)
with R2 association coefficients greater than or equal to 0.7
between the total, indirect, and health care costs and the
degree of interference in daily activities caused by the pain as
measured by the 11-point numeric rating scale. Finally, when
patients were classified according to item 5 of the EQ-5D
questionnaire (presence of symptoms of anxiety and/or
depression) based on no problems, some problems, and
extreme problems, statistically significant increases (P < 0.05)
were observed in total and indirect costs, but not in health care
costs with greater responses of problems (Figure 5).
Discussion
This study determined the incremental costs of patients with
FMS compared with a reference population using a local
health provider that nonetheless may be representative of
what occurs at many health care facilities in our current geo-
graphical environment. Incremental costs in relation to the ref-
erence population include the use of health care resources as
well as employment or earning losses due to absenteeism or
early retirement due to disability from regular employment
before the age of 65, the theoretical retirement age in Spain.
The analysis carried out shows that the most important com-
ponent of the cost of illness corresponds to indirect costs or
earnings losses, contributing approximately 81% in FM
patients, compared with 71% in the reference population.
Even though the relative data may not show the magnitude of
the cost and burden of illness, patients with FMS have a mean
incremental cost that is more than €5,000 greater annually
than that of the reference population (nearly €4,400 due to
earnings lost and more than €600 in direct health care
Table 4
Annual use and cost of health care and non-health care resources among study subjects by group
Resource/type of cost FMS patients
n = 1,081
Reference group
n = 62,445
Adjusted differences and/or odds ratio (95% CI) and P valuea
Mean annual use of health care and non-health care resources
GP office visits 13.5 (10.1) 7.7 (8.2) 5.0 (3.8–6.3); P < 0.001
Complementary testsb 0.4 (0.7) 0.2 (0.5) 0.3 (0.2–0.4); P < 0.001
Referrals 1.5 (1.6) 0.8 (1.1) 0.7 (0.5–0.8); P < 0.001
Emergency room visits 0.6 (1.1) 0.4 (0.8) 0.3 (0.2–0.4); P < 0.001
Hospitalizations, stays 1.48 (0.79) 1.47 (1.07) 0.44 (-0.29–1.17); P = 0.239
Sick leave, days 20.9 (57.2) 8.0 (30.7) 23.5 (18.3–28.7); P < 0.001
Premature retirement, %c 29.9 9.5 3.58 (3.13–4.10); P < 0.001d
Mean annualized costs in euros, total and disaggregated in components
Health care costs 1,677.3 (1,467.4) 934.8 (1,390.2) 613.6 (403.7–823.4); P < 0.001
Physician visitsb 424.0 (304.7) 233.5 (236.1) 171.7 (134.7–208.7); P < 0.001
Complementary tests 275.9 (282.8) 126.6 (198.6) 108.8 (77.2–140.3); P < 0.001
Hospitalizations 268.6 (760.1) 213.9 (783.9) 101.7 (-27.1–230.5); P = 0.122
Drugs 706.5 (840.8) 359.7 (710.2) 229.8 (124.1–335.4); P < 0.001
Non-health care costs 6,977.0 (9,256.6) 2,330.5 (6,100.9) 4,396.5 (3,373.2–5,419.8); P < 0.001
Sick leave 815.8 (2,565.3) 376.0 (1,486.1) 836.8 (587.1–1,086.5); P < 0.001
Early retirementc 6,161.2 (9,442.8) 1,954.5 (6,040.1) 3,559.7 (2,547.8–4,571.6); P < 0.001
Total cost 8,654.3 (9,645.7) 3,265.3 (6,421.5) 5,010.1 (3,494.0–6,076.2); P < 0.001
Values are presented as mean (standard deviation). aDifferences are adjusted for age and gender. bIncludes all types of medical visits, referrals, 
and emergency room visits. cPermanent disability for work as a consequence of fibromyalgia syndrome (FMS) before 65 years of age in active 
population only. dAdjusted odds ratio for age and gender. CI, confidence interval; GP, general practitioner.Available online http://arthritis-research.com/content/11/2/R54
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Figure 1
Ability of the impact of the disease (FIQ) to explain annual mean costs Ability of the impact of the disease (FIQ) to explain annual mean costs. The range of the FIQ is from 0 to 100. Explanatory ability assessed by linear 
regression models of decile values of the FIQ and corresponding costs at the decile interval of the instrument are shown. Cost values are expressed 
as inter-decile interval mean ± 95% confidence interval. FIQ, Fibromyalgia Impact Questionnaire.
Figure 2
Annual mean costs of fibromyalgia patients according to severity of pain as assessed by the Brief Pain Inventory (BPI) Annual mean costs of fibromyalgia patients according to severity of pain as assessed by the Brief Pain Inventory (BPI). The range of the BPI is from 
0 to 10. The three levels of pain severity are mild (BPI <4; n = 9), moderate (BPI ≥ 4 to <7; n = 76), and severe (BPI ≥ 7; n = 115). Total, indirect, 
and health care costs are shown.Arthritis Research & Therapy    Vol 11 No 2    Sicras-Mainar et al.
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resources), which (aside from being statistically significant)
appears to us to be a considerable economic burden to soci-
ety and is in line with that observed in pathologies classically
considered first-order health problems (such as generalized
anxiety or refractory epilepsy), once adjusted for currency and
year (around €6,000) [32-35], and is approximately half of the
cost observed in disorders such as vascular dementia and
Alzheimer-type dementia, which are considered to be health
disorders with a high economic burden on society [36,37].
Although losses of productivity due to early permanent disabil-
ity before the age of 65 and leave from employment make up
Figure 3
Annual mean costs of fibromyalgia patients according to severity of pain as assessed by the Brief Pain Inventory (BPI) Annual mean costs of fibromyalgia patients according to severity of pain as assessed by the Brief Pain Inventory (BPI). The range of the BPI is from 
0 to 10. The three levels of pain severity are mild (BPI <4; n = 9), moderate (BPI ≥ 4 to <7; n = 76), and severe (BPI ≥ 7; n = 115). Health care costs 
are split into components.
Figure 4
Ability of pain interference on patient's daily activities (BPI-I) to explain annual mean total costs Ability of pain interference on patient's daily activities (BPI-I) to explain annual mean total costs. The range of the BPI-I is from 0 to 10. Explanatory 
ability assessed by linear regression models of level of interference on the BPI-I and corresponding costs of patients grouped by instrument intervals 
of pain interference are shown. Cost values are expressed as mean ± 95% confidence interval of subjects included in each interval. BPI-I, Brief Pain 
Inventory – Pain interference subscale.Available online http://arthritis-research.com/content/11/2/R54
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the most significant part of the cost, it should be mentioned
that costs corresponding to health care resources were signif-
icantly higher in patients with FMS, with a mean annual excess
greater than €600. Of these, 42% corresponds to the cost of
pharmacological treatment, although this cost represents a
mere 8% of the total. Also, the use of an annual average of 3.7
medications in patients with FMS (significantly higher than the
1.4 medications used by the reference population) gives us an
idea of the difficulty of treating this syndrome and the degree
of inefficiency of the current therapeutic armaments available
for this health care problem. It is worth emphasizing that, with
the exception of hospital costs, the other components of the
health care cost (medical visits and supplementary tests, aside
from those due to medications) were significantly higher in
subjects with FMS and higher on the whole than that corre-
sponding to drug costs. More specifically, patients with FMS
had, in a 12-month period, six more medical visits on average
than the general population, which agrees with the data from
Hughes and colleagues [38], Wolfe and colleagues [39], and
Robinson and colleagues [11], who also noted an increase in
the use of medical services in FM patients which was much
greater than that observed in the reference groups.
Analyses relating costs with measurements of self-perceived
health have allowed us to prove the existing relationship
between greater costs and the increased impact of FM on
patient function (FIQ) and the intensity and interference of pain
which these subjects have in their daily lives (BPI). The linear
relationships found using the FIQ illustrated that an increase in
the impact of FM by one decile (for example, going from the
6th percentile, 78.9 points on the FIQ, to the 7th, 81.5 points)
increased total costs by approximately €865 annually. Regres-
sion analyses showed that the mean increment in costs men-
tioned above appeared with fewer scoring variations on the
FIQ at the decile intervals of greater impact of the illness
(above the fifth decile) than in the lower deciles. This means
that, when the impact of disease reaches a severe level, lower
increases of the impact are accompanied by higher cost incre-
ments. A similar phenomenon was observed using the BPI
using the pain interference index. For example, an increase in
the degree of pain interference by 1 point (0- to 10-point
scale) is associated with a total annual cost increase of
€1,453. Pain intensity measured with the BPI was significantly
associated with total, indirect, and health care costs as pain
intensity rose from mild to moderate to severe, although the
increase in health care costs was driven primarily by increased
medication costs. Finally, the presence of anxiety and/or
depression symptoms (question 5 of EQ-5D) showed signifi-
cantly higher total costs when the degree of anxiety/depres-
sion was severe, which was driven primarily by indirect costs.
We have not found any studies similar to ours in order to com-
pare our findings with other health care areas related to FMS
in our health care environment. However, when we compare
our results to those published by other authors in other con-
texts, some discrepancies are observed. For example, our
results differ greatly from those of a study by Berger and col-
leagues [14], which is also on the cost of FMS and performed
using an administrative database in the US. That study shows
that, after currency conversion and adjustment for the year of
Figure 5
Annual mean total, indirect, and health care costs of fibromyalgia patients according to degree of problems in item 5 (anxiety/depression) of the five- item questionnaire on European quality of life (EQ-5D) Annual mean total, indirect, and health care costs of fibromyalgia patients according to degree of problems in item 5 (anxiety/depression) of the five-
item questionnaire on European quality of life (EQ-5D).Arthritis Research & Therapy    Vol 11 No 2    Sicras-Mainar et al.
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the study, costs are similar in amount to ours, but only reflect-
ing direct health care costs. The explanation for this difference
could be that these are very different health care systems with
very disparate fees and prices and even with distinct assist-
ance protocols. However, results more similar to ours were
observed in other studies, both in the US and in Canada
[15,39], and above all, it was shown that comorbid depression
significantly increased total costs [40]. These results were
more coherent with our findings in that the presence of severe
anxiety and/or depression problems existing alongside FMS
significantly increased the total costs of the illness (in particu-
lar, indirect costs).
This work has allowed us also to explore the burden of the ill-
ness relative to the concurrent presence of other health disor-
ders along with FMS. First, the prevalence of FMS in our
population was slightly less than the national total, 1.7% ver-
sus 2.4%, with clear higher frequency in females [5]. What is
remarkably noticeable is the high number of comorbid disor-
ders that are significantly more frequent in patients with FMS
than in the general reference population, as was previously
indicated [41-43]. Thus, not only is there greater psychiatric
comorbidity [44,45], but in the recent OMERACT (Outcome
Measures in Rheumatoid Arthritis Clinical Trials) Delphi study
[41], we also observed a greater presence of pain syndromes
(20.5% versus 5.5%, 2.9 times more frequent), a greater prev-
alence of obesity/weight gain (41%), lipidic metabolism disor-
ders (total cholesterol, low-density lipoprotein cholesterol, and
triglycerides significantly higher than in the general popula-
tion), migraines, and digestive disorders such as gastro-
esophageal reflux, gastritis, or irritable bowel, which are health
disorders (already seen in other studies) that proved to be
more prevalent in patients with FMS than in the general popu-
lation, as reflected by the type of medication and greater con-
sumption of medications by these patients [4,5,7,11,14,15,
38,39,41].
This study has some limitations that must be pointed out. First
are those which are relative to its cross-sectional and retro-
spective design, though usual for this type of study, which ena-
ble the potential underestimation of some costs relative to
resources consumed outside of the BSA system or those not
accurately recorded in the computer system of this health care
provider. Given the quality of system data collection, subject
to periodic monitoring for quality and motivation, and the infre-
quency of patient referrals to other health care systems, this
potential underestimation of the costs is slight. However, we
should recognize that costs have been underestimated with
regard to 'out-of-pocket expenses', meaning those costs that
are borne solely by the patient, such as special diets, modifi-
cations to their residences, or non-pharmacological treat-
ments (massages, hydrotherapy, acupuncture, and so on) and
that are not usually included in the BSA database and, as
such, have not been taken into account in this study. On the
other hand, this study has not provided a cost for disability
days from any activity either in the retired population such as
domestic chores (preparing food, ironing, and so on) or in lei-
sure activities, as indicated by some health care economics
experts. Nonetheless, given the academic controversy over
the applicability of a monetary value to these costs, we
decided not to include them in this study. Another possible lim-
itation refers to the system followed to code diseases, the
ICD-10v10. Even the ICD-10 coding replaced the version 9 to
avoid misclassification detected in the oldest versions; we
cannot guarantee completely that a proportion of subjects in
the BSA database could not be correctly classified with an
FMS diagnosis. Or even the opposite could have happened:
patients without FMS could have received a code for FMS.
Another potential limitation refers to the administration of the
instruments of self-perceived health (FIQ, EQ-5D, and BPI)
over the telephone and doubts that this could produce reliable
responses from patients. Although it is true that administration
was performed without computer support (computer-assisted
telephone interviews or a similar method), these instruments
nonetheless have been used quite frequently in mail surveys
sent to homes and are instruments that are easy to understand
and well used in daily clinical practice, which is why we believe
that the errors in the degree of accuracy should be minor.
Conclusions
Taking into account the above-mentioned limitations, this
study has determined the incremental costs to society for
patients with FM in relation to the reference population and
has related this to the level of pain, impact, and interference of
the illness on the patients' daily lives. Our analysis shows that
the cost of illness of this syndrome is substantial, particularly
in relation to employment losses, which make up around four
fifths of the illness cost, which should encourage clinics,
health decision-makers, and health care authorities to set in
motion some social-health measures that would contribute to
the reduction of these alarming costs. Lastly, but by no means
less importantly, the high use of health care resources relative
to the reference population in the number of all types of medi-
cal visits as well as supplementary tests and drugs (which
shows the level of inability and inefficiency of the health care
resources currently available to clinics to alleviate the impact
of this syndrome on the quality of life for these patients) should
be indicated and should also motivate reflection upon this mat-
ter and a search for new solutions in the diagnostic and thera-
peutic management of FMS patients.
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